Systemic Lupus Erythematosus

What is Systemic Lupus Erythematosus?

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease where the body’s immune system attacks its own healthy tissues and organs. This condition can affect virtually any organ system, including the skin, joints, kidneys, heart, lungs, blood vessels, and brain. SLE predominantly affects women of childbearing age, with a female-to-male ratio of approximately 9:1. The disease affects an estimated 5 million people worldwide, with significant variation in prevalence across different ethnic groups.

Key statistics

Symptoms

Common early symptoms: Fatigue, joint pain and swelling, skin rashes (especially the characteristic butterfly rash across the cheeks), fever, hair loss, mouth ulcers.

Detailed symptom descriptions:

The hallmark butterfly rash appears as a red, flat or raised rash across both cheeks and the bridge of the nose. Joint pain typically affects multiple joints symmetrically, particularly in the hands, wrists, and knees, but unlike rheumatoid arthritis, rarely causes permanent joint damage. Extreme fatigue is often one of the most debilitating symptoms, persisting even with adequate rest.

Submit Your Paper

Serious complications include: Kidney involvement (lupus nephritis) causing protein in urine, high blood pressure, and potential kidney failure. Neurological symptoms may include seizures, confusion, memory problems, or stroke. Cardiovascular complications can involve inflammation of the heart muscle or lining. Blood disorders may cause anemia, low white blood cell count, or dangerous clotting problems.

Causes and risk factors

SLE is caused by a complex interaction between genetic predisposition and environmental triggers. The exact cause remains unknown, but research suggests multiple genes contribute to susceptibility, with over 100 genetic variants identified as risk factors.

Environmental triggers include: Epstein-Barr virus and other viral infections, ultraviolet light exposure, certain medications (such as hydralazine, procainamide, and some antibiotics), extreme stress, and pregnancy.

Risk factors: Female sex, age 15-45 years, African, Hispanic, Asian, or Native American ancestry, family history of lupus or other autoimmune diseases, and certain genetic markers including specific HLA types.

Prevention

Currently, there is no known way to prevent systemic lupus erythematosus due to its complex genetic and environmental causes. However, individuals with family history can take steps to reduce potential triggers: avoiding excessive sun exposure by using broad-spectrum sunscreen and protective clothing, managing stress through relaxation techniques, maintaining a healthy lifestyle with regular exercise and adequate sleep, and avoiding known medication triggers when possible. Early recognition of symptoms and prompt medical attention can help prevent serious complications and organ damage.

Complications

Without proper treatment, SLE can cause irreversible damage to multiple organ systems. Lupus nephritis affects 40-60% of patients and can progress to end-stage kidney disease requiring dialysis or transplantation. Neuropsychiatric complications occur in up to 75% of patients and may include cognitive dysfunction, mood disorders, seizures, or stroke.

Cardiovascular complications include accelerated atherosclerosis, leading to increased risk of heart attack and stroke at a young age. Bone complications include osteoporosis from chronic inflammation and corticosteroid use, plus avascular necrosis causing bone death. Pregnancy complications may include preeclampsia, preterm birth, and neonatal lupus in babies.

Diagnosis

SLE diagnosis relies on clinical criteria established by the American College of Rheumatology and the Systemic Lupus International Collaborating Clinics. No single test can diagnose lupus definitively.

Blood tests include: Antinuclear antibody (ANA) test, which is positive in 95% of lupus patients. Specific antibodies like anti-double-stranded DNA, anti-Smith, anti-SSA/Ro, and anti-SSB/La antibodies. Complement levels (C3 and C4) are often low during active disease. Complete blood count may show anemia, low white blood cell count, or low platelet count.

Additional tests: Urinalysis to detect kidney involvement, chest X-rays, echocardiogram, and sometimes kidney biopsy to assess lupus nephritis severity.

Treatment

Treatment focuses on controlling inflammation, preventing organ damage, and managing symptoms. Medications are tailored to disease severity and organ involvement.

First-line treatments: Hydroxychloroquine is prescribed for nearly all patients to reduce flares and protect against organ damage. Nonsteroidal anti-inflammatory drugs (NSAIDs) help manage joint pain and inflammation.

Immunosuppressive medications: Methotrexate, azathioprine, and mycophenolate mofetil are used for moderate to severe disease. Cyclophosphamide is reserved for severe kidney or nervous system involvement.

Biologic therapies: Belimumab is approved for refractory cases. Rituximab may be used off-label for severe disease. Corticosteroids like prednisone provide rapid control during flares but are minimized due to side effects.

Prognosis

The prognosis for SLE has improved dramatically over the past several decades. With early diagnosis and appropriate treatment, 10-year survival rates exceed 80-90%. However, prognosis varies significantly based on organ involvement, with kidney and nervous system involvement carrying more serious implications.

Factors associated with better outcomes include early diagnosis, good adherence to treatment, absence of kidney involvement, and younger age at diagnosis. The disease typically follows a relapsing-remitting course, with periods of increased activity (flares) alternating with periods of remission. Long-term monitoring is essential as complications can develop years after initial diagnosis.

Quality of life

Living with lupus requires significant lifestyle adjustments and ongoing medical management. Sun protection is crucial, requiring daily use of broad-spectrum sunscreen, protective clothing, and avoiding peak sun hours. Regular, gentle exercise like swimming, walking, or yoga can help maintain joint flexibility and reduce fatigue, though activities should be modified during flares.

Stress management through meditation, counseling, or support groups is important as stress can trigger flares. Adequate sleep (7-9 hours nightly) and maintaining consistent sleep schedules help manage fatigue. A balanced, anti-inflammatory diet rich in calcium and vitamin D supports bone health, especially important for those taking corticosteroids.

Workplace accommodations may include flexible scheduling, reduced physical demands, or work-from-home options during flares. Mental health support is crucial, as depression and anxiety are common. Building a strong support network through family, friends, and patient organizations significantly improves coping and quality of life.

Pregnancy and fertility

SLE can affect fertility and pregnancy outcomes, but many women with lupus have successful pregnancies with careful planning and monitoring. Pregnancy should ideally be planned during periods of disease remission (at least 6 months of stable, low disease activity).

Pregnancy risks include increased risk of preeclampsia, preterm birth, intrauterine growth restriction, and blood clots. Women with anti-SSA/Ro or anti-SSB/La antibodies face risk of neonatal lupus in their babies, which can cause heart block.

Medication adjustments are necessary before conception, as some drugs like methotrexate and cyclophosphamide are teratogenic. Hydroxychloroquine is safe and should be continued during pregnancy. Preconception counseling with rheumatology and high-risk obstetrics specialists is essential.

Children

Pediatric lupus accounts for 10-20% of all SLE cases, typically presenting after age 10. Children often have more severe disease at onset, with higher rates of kidney and nervous system involvement compared to adults.

Growth and development may be affected by chronic inflammation and corticosteroid use. School accommodations may include modified physical education, extra time for assignments during flares, and flexibility for medical appointments. Transition planning to adult care typically begins in mid-adolescence, with gradual transfer of disease management responsibility to the teenager.

Vaccination schedules may need modification, with live vaccines generally avoided in immunosuppressed children. Regular ophthalmologic monitoring is important due to hydroxychloroquine use.

When to see a doctor

Seek immediate medical attention for: Severe headaches with fever, confusion, or vision changes suggesting nervous system involvement. Chest pain or difficulty breathing may indicate heart or lung complications. Decreased urination, swelling, or foamy urine suggests kidney problems. High fever, severe abdominal pain, or signs of infection in immunosuppressed patients require urgent evaluation.

Routine monitoring includes: Regular follow-ups every 3-6 months during stable disease, with laboratory monitoring for disease activity and medication side effects. Annual eye exams for patients taking hydroxychloroquine. Bone density screening for those on long-term corticosteroids.

Regional context

Limited data exists on SLE prevalence specifically in the Caucasus region. However, studies suggest that Middle Eastern and Mediterranean populations may have intermediate prevalence rates compared to the higher rates seen in African and Hispanic populations and lower rates in Northern European populations. Environmental factors such as increased sun exposure in the region may influence disease expression and require particular attention to sun protection strategies. GMJ welcomes contributions from regional researchers to build the evidence base for systemic lupus erythematosus in the Caucasus.

Research and clinical trials

Current research focuses on developing more targeted therapies with fewer side effects. Promising areas include CAR-T cell therapy, which has shown remarkable results in small studies for refractory lupus. New biologic agents targeting different immune pathways are in development, including agents targeting type I interferons and complement pathways.

Biomarker research aims to predict flares and treatment responses, potentially allowing for more personalized medicine approaches. Clinical trials are investigating combination therapies and novel drug delivery methods. Patients can search for relevant clinical trials at ClinicalTrials.gov using keywords “systemic lupus erythematosus.”

Frequently asked questions

Is lupus contagious?

No, lupus is not contagious. It cannot be transmitted from person to person through any form of contact. It is an autoimmune disease caused by genetic and environmental factors.

Can diet help manage lupus symptoms?

While no specific diet cures lupus, an anti-inflammatory diet rich in omega-3 fatty acids, fruits, vegetables, and whole grains may help reduce inflammation. Calcium and vitamin D are important for bone health, especially for patients taking corticosteroids.

Will I need to take medication for life?

Most people with lupus require long-term medication to prevent flares and organ damage. Hydroxychloroquine is typically continued indefinitely, while other medications may be adjusted based on disease activity.

Can I have children if I have lupus?

Yes, many women with lupus have successful pregnancies. However, pregnancy requires careful planning during disease remission and close monitoring by specialists familiar with lupus in pregnancy.

Is lupus fatal?

With modern treatment, most people with lupus live normal or near-normal lifespans. The 10-year survival rate exceeds 90%, and many patients live decades with well-controlled disease.

Support and resources

International organizations:
– Lupus Foundation of America (www.lupus.org)
– Lupus Europe (www.lupus-europe.org)
– World Lupus Federation (www.worldlupusfederation.org)
– Lupus Research Alliance (www.lupusresearch.org)
– Systemic Lupus Erythematosus International Collaborating Clinics (www.slicc.ca)

Research and information:
– National Institute of Arthritis and Musculoskeletal Diseases (www.niams.nih.gov)
– Orphanet (www.orpha.net)
– ClinicalTrials.gov for research opportunities

Related conditions

Antiphospholipid syndrome – An autoimmune condition causing abnormal blood clotting that frequently occurs with lupus.

Sjögren’s syndrome – An autoimmune disease affecting salivary and tear glands, often overlapping with lupus.

Rheumatoid arthritis – Another systemic autoimmune disease primarily affecting joints.

Systemic sclerosis – An autoimmune connective tissue disease causing skin and organ fibrosis.

Mixed connective tissue disease – A condition sharing features of lupus, scleroderma, and myositis.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.